A Phase II Study of NK012, a Polymeric Micelle Formulation of SN-38, in Unresectable, Metastatic or Recurrent Colorectal Cancer Patients

Cancer Chemotherapy and Pharmacology - Germany
doi 10.1007/s00280-018-3693-6
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Novel SN-38-Incorporated Polymeric Micelle, NK012, Strongly Suppresses Renal Cancer Progression

Cancer Research
Cancer ResearchOncology
2008English

A Phase II Study of Axalimogene Filolisbac for Patients With Previously Treated, Unresectable, Persistent/Recurrent Loco-Regional or Metastatic Anal Cancer

Oncotarget
Oncology
2020English

Phase II Study of Aflibercept (VEGF-Trap) in Patients With Recurrent or Metastatic Urothelial Cancer, a California Cancer Consortium Trial

Urology
Urology
2010English

A Phase II Trial of Gemcitabine and Capecitabine in Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma: Southwest Oncology Group Study S0202

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2011English

SWOG 0514: A Phase II Study of Sorafenib in Patients With Unresectable or Metastatic Gallbladder Carcinoma and Cholangiocarcinoma

Investigational New Drugs
OncologyPharmacology
2011English

Phase I/Ii Study of S-1 Combined With Paclitaxel in Patients With Unresectable and/or Recurrent Advanced Gastric Cancer

British Journal of Cancer
Cancer ResearchOncology
2006English

A Phase II Study of Carboplatin in Advanced or Metastatic Stomach Cancer

European Journal of Cancer and Clinical Oncology
1987English

Results of a Prospective Phase 2 Study of Pazopanib in Patients With Surgically Unresectable or Metastatic Chondrosarcoma

Cancer
Cancer ResearchOncology
2019English

Novel SN-38-Incorporating Polymeric Micelles, NK012, Eradicate Vascular Endothelial Growth Factor-Secreting Bulky Tumors

Cancer Research
Cancer ResearchOncology
2006English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy